相关实验视频

Updated: Jul 7, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

在激素受体阳性乳腺癌中准CDK6:通过动态研究研究发现精密瘤学的抑制剂

Zeenat Khatoon¹, Mohammad Khalid², Mohammed H Alqarni²

¹Class One Systems S&T Pvt. Ltd., New Delhi, India.

Journal of biomolecular structure & dynamics

|December 21, 2023

概括

这项研究确定了两个新型化合物CDK6-IMPHY002642和CDK6-IMPHY005260作为CDK6.6的潜在抑制剂. 这些化合物通过调节细胞循环进展,对乳腺癌的向治疗具有前途.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

循环素依赖性激酶6 (CDK6) 对于细胞周期调节至关重要,特别是G1到S阶段的进展.
失调的CDK6与乳腺癌的发展和进展有关,特别是在激素受体阳性亚型中.
在某些乳腺癌中,CDK6的上调驱动不受控制的细胞增殖.

研究的目的:

研究CDK6在乳腺癌中的作用.
用特定的抑制剂识别和评估针对CDK6的新型治疗策略.
通过计算查和模拟来发现可行的药物候选者.

主要方法:

使用高吞吐量选和分子对接研究来确定潜在的CDK6抑制剂.
对化合物进行了ADMET特性和活性谱的分析.
对选定的化合物进行了分子动力学 (MD) 模拟.

主要成果:

两个化合物CDK6-IMPHY002642和CDK6-IMPHY005260被确定为潜在的CDK6抑制剂.
MD模拟表明CDK6和已识别的化合物之间存在稳定的复合物形成.
鉴定的化合物显示出作为治疗剂的潜力.

结论:

CDK6-IMPHY002642和CDK6-IMPHY005260是乳腺癌治疗中进一步研究的有希望的候选人.
针对CDK6,结合遗传分析,为精确瘤学提供了一条途径.
早期诊断和利用CDK6的目标驱动疗法是未来干预的关键.

关键词:

在ADMET中,ADMET的属性是:循环素依赖性激酶6的作用模拟MDMD的模拟自由能源的景观.高吞吐量选的高吞吐量选

更多相关视频

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...